Nonalcoholic Steatohepatitis (NASH): From Molecular Mechanisms to Therapeutic Opportunities

Dear Colleagues, 

Nonalcoholic fatty liver disease (NAFLD), along with its progressive form of disease the nonalcoholic Steatohepatitis (NASH), is the most common chronic liver disease in the Western world. The prevalence of this disease is rapidly increasing in the rest of the world population. Despite increasing awareness and research in mitigating the disease, readily available diagnostic biomarkers and definitive pharmacological therapy are unavailable. This could become an increasing concern as the prevalence of this disease grows in the population, especially in certain parts, such as the USA, where more than 50% have fatty liver disease. In this regard, a deeper understanding of the molecular mechanisms of the disease process will guide us to serve the community at large. 

The emphasis of this Special Issue is on the recent understanding and advances in the pathophysiology of NAFLD and NASH progression, genomics in NASH, the role of adaptive immunity in NASH, the molecular and cellular mechanisms of fibrosis in NASH, omics and biomarkers, the gut microbiome in NAFLD, the consideration of unique populations, including NASH in the pediatric population and lean NASH, available pharmacological agents and phase 3 drugs for management, and possible new interventions (phase 2 trial drugs) based on treatment targets. 

I look forward to receiving your contributions and compiling this exciting Special Issue. 

Dr. Achuthan Sourianarayanane
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.